

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/870,932
		Filing Date	May 30, 2001
		First Named Inventor	Wu, Lijun, et al
		Group Art Unit	1647
		Examiner Name	Sharon L. Turner
Sheet 1 of 1	Attorney Docket Number	MPI96-027CP2RCE2M	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	AR7	AHUJA, SUNIL K. et al., "CXC Chemokines Bind to Unique Sets of Selectivity Determinants That Can Function Independently and Are Broadly Distributed on Multiple Domains of Human Interleukin-8 Receptor B" <i>The Journal of Biological Chemistry</i> , Vol 271, No 1, January 5, 1996, pp. 225-232.	
	AR8	CHUNTHARAPAI, A., et al. "Neutralizing Monoclonal Antibodies to Human IL-8 Receptor A Map to the NH ₂ -Terminal Region of the Receptor" <i>Journal of Immunology</i> , November 23, 1993, pp. 1783-1789.	

Examiner Signature		Date Considered	1-11-06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.